Bal Pharma Limited

BALPHARMA

INE083D01012

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:51 12/06/2024 BST			5-day change	1st Jan Change
120.6 ^INR	-0.17%		+12.09%	+19.95%

05-28	Bal Pharma Limited Recommends Dividend	CI
05-28	Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Bal Pharma Limited Appoints S.Anika Mercylin as Company Secretary and Compliance Officer

December 27, 2018 at 07:09 am

The Board of Directors of Bal Pharma Limited at their meeting held on December 27, 2018 has inter alia appointed Ms. S.Anika Mercylin as Company Secretary and Compliance officer of the Company.

Latest news about Bal Pharma Limited

Bal Pharma Limited Recommends Dividend	05-28	CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-28	CI
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Bal Pharma Limited Approves Dividend	25/09/23	CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/08/23	CI
Bal Pharma Limited Appoints Abdul Basith as Company Secretary and Compliance Officer	17/07/23	CI
Bal Pharma Limited Appoints Nicola Neeladri as Additional Director	01/06/23	CI
Bal Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/05/23	CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/05/23	CI
Bal Pharma Limited Recommends Dividend	29/05/23	CI
Bal Pharma Limited Announces Resignation of Mrs.Preeti Singh as Company Secretary	15/05/23	CI
Acuite Keeps BBB- Rating on Bal Pharma's Bank Loans; Outlook Stable	25/04/23	MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	06/02/23	CI
Bal Pharma CFO Resigns	25/11/22	MT
Bal Pharma Limited Announces Resignation of Mr. G. Rengarajan as Chief Financial Officer	24/11/22	CI
Bal Pharma Limited Reports Earnings Results for the Half Year Ended September 30, 2022	14/11/22	CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Bal Pharma Limited Declares Dividend	19/09/22	CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	11/08/22	CI
Bal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent)	30/05/22	CI
Bal Pharma Limited Recommends Dividend	30/05/22	CI
Acuite Upgrades Rating on Bal Pharma's Fund-Based Financing to BBB-; Lowers Outlook to Stable	22/02/22	MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	10/02/22	CI
ICRA Maintains BB+ Rating on Bal Pharma's Long-Term Bank Financing; Raises Outlook to Positive	22/12/21	MT

Bal Pharma Limited is a pharmaceutical company, which is engaged in manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It is specialized in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers range of APIs includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers range of formulations products covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAL PHARMA LIMITED	+19.95%	22.65M
ELI LILLY AND COMPANY	+48.79%	780B
NOVO NORDISK A/S	+41.76%	627B
MERCK & CO., INC.	+19.43%	334B
ABBVIE INC.	+7.18%	296B
ASTRAZENECA PLC	+17.60%	244B
ROCHE HOLDING AG	-0.41%	217B
NOVARTIS AG	+11.54%	214B
AMGEN INC.	+4.53%	161B
PFIZER, INC.	-3.92%	159B

Other Pharmaceuticals